Aligning on Affordability Program Cost Exposure at Launch
The Challenge
A large oncology manufacturer is launching a new infused therapy. Product approval/ launch expected in a year and the patient services group needed to develop a cost forecast for their anticipated access, affordability, and adherence programs and provide the corresponding assumptions and rationale. The pharmaceutical company is looking to understand the costs of providing a robust patient support experience for one of their oncology brands that will help them forecast future budgets.
Goal: Analyze & model how to best support the financial needs of patients seeking access to therapy as it relates to the patient assistance program (PAP), Medicare Advantage, copay, biomarker testing, side effect management, and gaps addressed by providing starter and bridge therapy.
Our Solutions
- Analyzed Competitor Analogs
- Forecasted Cost Impacts
- Developed Financial Models
The Results
Robust and Interactive Models
Multiple interactive financial models delivered that can be updated and adjusted as new insights are discovered over the launch preparation timeline
Financial Assistance Knowledge
Team gained industry and financial support knowledge that can be leveraged in the future across multiple brands
Leadership Peace-of-Mind
Strong rationale and analogs provided in a concise executive summary for leadership understanding & approval
“The cost modeling and forecast was very robust, and the consolidated presentation made it easy to explain to marketing and finance what we could expect and why.”- Patient Services Director
Download Case Study: Aligning on Affordability Program Cost Exposure at Launch
